TIL Therapy for Solid Tumors Is Scaling Up: What Amtagvi's Growth Means for Patients

Amtagvi (lifileucel), the first FDA-approved tumor-infiltrating lymphocyte (TIL) cell therapy for a solid tumor, is moving from a narrow melanoma launch into a broader manufacturing and distribution network — and its maker, Iovance Biotherapeutics, is now testing the same one-time cell therapy in soft-tissue sarcoma and lung cancer. This piece covers what the technology does inside the body, what Iovance's newest quarterly numbers show, how serious the toxicity profile is, and why "more treatment centers" is a different milestone than "proven in a new cancer type."

A Real Growth Story, With Real Numbers Behind It

Iovance's second-quarter 2026 results, reported August 6, 2026, describe a business genuinely expanding two years after Amtagvi's initial approval. The company posted total revenue of roughly $99.3 million — about 66% higher than the same quarter a year earlier — with U.S. Amtagvi sales making up around $91 million of that and a gross margin near 56%. For a personalized therapy built around shipping a patient's tumor tissue out and a living cell product back, that growth signals the operational machinery is starting to work at scale rather than remaining a boutique, single-site process.

The network of Authorized Treatment Centers (ATCs) — hospitals certified to administer Amtagvi — has grown to more than 95 sites across the U.S., Canada, and Australia, with Iovance projecting at least 110 by year-end 2026. Roughly a third of the network is community cancer centers rather than large academic hubs, notable for a therapy whose 2024 rollout leaned heavily on major transplant centers. Manufacturing turnaround — sample-received to product-shipped — is now reported at 31 days or less, down from roughly 34 at launch. These are company-reported figures from an earnings release, not independently audited benchmarks, but they track with the learning curve you'd expect as a first-of-its-kind manufacturing process matures.

What TIL Therapy Actually Is

Tumor-infiltrating lymphocyte therapy is built on a straightforward idea: T cells already living inside a tumor have proven, by virtue of being there, that they can recognize that specific patient's cancer. Inside the tumor's immunosuppressive environment, though, those T cells are typically outnumbered and exhausted. TIL therapy pulls them out, grows them into an army outside the body, and puts them back.

A piece of the patient's tumor is surgically removed and shipped to a manufacturing facility, where T cells are isolated and expanded over roughly two to three weeks — with interleukin-2 (IL-2) driving proliferation — into a dose of tens of billions of cells. While manufacturing proceeds, the patient undergoes high-dose lymphodepleting chemotherapy, clearing existing immune cells to make physiological "room" for the incoming TILs. The expanded product is infused back in a single one-time treatment, followed by additional IL-2. Unlike CAR T-cell therapies, which genetically re-engineer a patient's blood-derived T cells, lifileucel uses T cells that already exist naturally — the National Cancer Institute describes this as leveraging cells that have already shown an ability to find and infiltrate the cancer on their own.

Amtagvi's original approval, granted February 16, 2024, was an accelerated approval — not a full approval — for adults with unresectable or metastatic melanoma progressing after a PD-1-blocking antibody (and a BRAF inhibitor, if BRAF V600-mutated). It rested on a single-arm, open-label trial rather than a randomized study: among 73 evaluable patients, the objective response rate was 31.5%. Accelerated approval means the FDA judged the data likely to predict clinical benefit, with confirmatory trials still required — a distinction worth remembering as the therapy moves into new cancer types.

The Toxicity Side of the Ledger

Amtagvi is not a low-risk outpatient infusion, and its label reflects that directly. The FDA-mandated boxed warning covers prolonged severe low blood counts (cytopenia), internal organ hemorrhage, and severe infection, and requires administration in a hospital setting with intensive care capability on hand. In the trial population underlying the approval, treatment-related mortality was reported at 7.5%, with deaths attributed to severe infection, internal hemorrhage, acute kidney failure, respiratory failure, and cardiac arrhythmias. Grade 3-or-higher cytopenia persisted beyond 30 days in nearly half of patients (45.5%), treatment-related infections occurred in roughly 27%, and febrile neutropenia affected close to half. Very common reactions — in most patients — included chills, fever, nausea, fatigue, diarrhea, and rapid heart rate, largely from the preparatory chemotherapy and IL-2 support. This is a resource-intensive intervention no community oncology practice can administer without specialized inpatient infrastructure — precisely why the Authorized Treatment Center model exists.

Why the Treatment Center Network Is the Real Bottleneck

Because Amtagvi must be manufactured individually from each patient's tumor sample, shipped to and from a centralized facility, and administered by a team equipped for severe toxicity and possible ICU-level complications, geography and hospital capability function as hard access limits that don't apply to an oral drug. At 2024 launch, Iovance began with around 30 active centers, aiming for 50 within 90 days; coverage at the time flagged open questions about whether early sites had fully built out the needed capability. Growth to 95-plus sites, a third of them community centers, shows that build-out is continuing — but even 110 sites across three countries by year-end 2026 leaves large stretches of geography without a nearby center. Layered on top is cost: Amtagvi launched at roughly $515,000 per patient, the highest of any cell-based cancer medicine in the U.S. at the time, raising its own questions around insurance coverage and travel during a multi-week treatment process.

New Frontiers: What's Actually Been Shown, and What Hasn't

Iovance's August 2026 update also touts FDA Fast Track Designations for lifileucel in two soft-tissue sarcoma subtypes — undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) — and, separately, in previously treated metastatic non-squamous NSCLC. Fast Track status speeds up FDA interactions for drugs addressing unmet need; it is not evidence of efficacy and does not mean the therapy works in these cancers, only that the agency agreed the program merits expedited engagement.

It's worth being precise about where the widely cited "50% objective response rate" comes from, since two ongoing programs are easy to conflate. The 50% figure is from Iovance's early SARATOGA trial (IOV-SAR-201, an open-label Phase 1 study) in soft-tissue sarcoma — reflecting just six evaluable patients, reported February 2026, with the company framing it as encouraging against a historical benchmark of well under 5% response rates in second-line treatment for this cancer. That is an extremely small, uncontrolled, company-reported early readout, not a confirmed or peer-reviewed finding; fuller results are expected at a medical meeting later in 2026. The lung cancer program is separate and more mature: the registrational Phase 2 IOV-LUNG-202 trial, an interim single-arm analysis of 39 previously treated advanced nonsquamous NSCLC patients (data cut October 2025), showed an objective response rate of roughly 26% (10 of 39 patients), with a disease control rate near 72%. Neither trial has a randomized comparator arm, and neither means lifileucel is "proven" effective in sarcoma or lung cancer — both remain investigational, well short of the evidence bar behind the original accelerated melanoma approval.

Bottom Line

The operational story here is real: Iovance is manufacturing and delivering a highly complex, individualized cell therapy faster and at more sites than a year or two ago, and that scaling is genuinely hard for any cell therapy company to pull off. But growth in revenue and treatment-center count is a business milestone, not a clinical one — it says nothing new about how well lifileucel works in melanoma, and even less about sarcoma or lung cancer, where the data remain early, small, uncontrolled, and company-reported. If you or a family member is considering Amtagvi, or being approached about a sarcoma or lung cancer trial involving lifileucel, ask your oncologist directly: what is the actual evidence behind this specific indication (full versus accelerated approval versus a Fast Track-designated trial), what does your hospital's Authorized Treatment Center status mean for staffing and ICU backup, what would the full course of chemotherapy, infusion, and recovery look like personally, and what would it cost after your specific insurance coverage.